A Study of Ralinepag to Evaluate Effects on Exercise Capacity by CPET in Subjects With WHO Group 1 PH (CAPACITY)

NCT04084678 PHASE3 TERMINATED

Study ROR-PH-302, ADVANCE CAPACITY, is designed to evaluate the effects of ralinepag therapy on exercise capacity as assessed by change in peak oxygen consumption (VO2) derived from cardiopulmonary exercise testing (CPET) after 28 weeks of treatment

Details

Lead sponsor	United Therapeutics
Phase	PHASE3
Status	TERMINATED
Enrolment	10
Start date	Wed Jan 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Apr 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• PAH
• Pulmonary Hypertension
• Hypertension
• Connective Tissue Disease
• Familial Primary Pulmonary Hypertension
• Vascular Diseases
• Cardiovascular Diseases
• Hypertension, Pulmonary
• Lung Diseases
• Respiratory Tract Disease

Interventions

• Ralinepag
• Placebo

Countries

Italy, Belgium, Austria, United Kingdom, Germany, Poland, Argentina, Canada, Australia, Spain, United States, Brazil